New hope for Tough-to-Treat breast cancer: trial tests experimental drug
NCT ID NCT07417241
Summary
This study is testing whether a new drug called SHR-A1811 works better and is safer than the current standard treatment for people with advanced HER2-positive breast cancer whose cancer stopped responding to their first targeted therapy. About 100 adults with this specific type of breast cancer will be randomly assigned to receive either the new drug or the standard combination of two other drugs. The main goal is to see which treatment keeps the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.